Humana's Q3 2020 earnings were impacted by increasing utilization, COVID-19 testing and treatment costs, and crisis relief efforts. The company reported GAAP EPS of $10.05 and Adjusted EPS of $3.08. Humana anticipates fourth quarter losses to reflect continued support for its constituents, along with the impact of increasing utilization, and COVID-19 testing and treatment costs.
Continued emphasis on actions to alleviate financial burdens and other hardships for its members, providers, employees, and communities during the COVID-19 pandemic.
Achieved 92 percent, or 4.1 million of the company's Medicare Advantage members currently enrolled in 4-Star and above contracts for 2021, including 960,000 members in 4.5 Star contracts and a 5-Star rated contract in Florida.
Reported 3Q20 earnings per diluted common share (EPS) of $10.05 on a GAAP basis, $3.08 on an Adjusted basis; reports YTD 2020 EPS of $27.37 on a GAAP basis, $21.04 on an Adjusted basis
Increased full year expected individual Medicare Advantage membership growth to approximately 375,000 members from the previous range of 330,000 to 360,000 members, representing expected year-over-year growth of approximately 10 percent
Humana adjusted its GAAP and Adjusted EPS guidance ranges for the year ended December 31, 2020 (FY20).
Analyze how earnings announcements historically affect stock price performance